Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7268)
All Articles published online
|
Publishing Process of This Article
|
Dec 28, 2015 (publication date) through May 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Radiology
ISSN
1949-8470
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Tsumura H, Satoh T, Ishiyama H, Hirano S, Tabata KI, Kurosaka S, Matsumoto K, Fujita T, Kitano M, Baba S, Hayakawa K, Iwamura M. Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapy. World J Radiol 2015; 7(12): 494-500 [PMID: 26753064 DOI: 10.4329/wjr.v7.i12.494] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8470/full/v7/i12/494.htm |
| Number | Citing Articles |
| 1 |
M. Dosani, W.J. Morris, S. Tyldesley, T. Pickles. The Relationship between Hot Flashes and Testosterone Recovery after 12 Months of Androgen Suppression for Men with Localised Prostate Cancer in the ASCENDE-RT Trial. Clinical Oncology 2017; 29(10): 696 doi: 10.1016/j.clon.2017.06.009
|
| 2 |
Julie Abildgaard, Hein Vincent Stroomberg, A Kirstine Bang, Jakob Albrethsen, Laura Smedegaard Kruuse, Anders Juul, Klaus Brasso, Andreas Røder, Niels Jørgensen. Pituitary-testis axis dysfunction following adjuvant androgen deprivation therapy. Endocrine-Related Cancer 2023; 30(1) doi: 10.1530/ERC-22-0246
|
| 3 |
Jessica Y. Hsueh, Lindsey Gallagher, Min Ji Koh, Shaine Eden, Sarthak Shah, Markus Wells, Malika Danner, Alan Zwart, Marilyn Ayoob, Deepak Kumar, Paul Leger, Nancy A. Dawson, Simeng Suy, Rachel Rubin, Sean P. Collins. Impact of neoadjuvant relugolix on patient-reported sexual function and bother. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1377103
|
| 4 |
Jae-Uk Jeong, Taek-Keun Nam, Ju-Young Song, Mee Sun Yoon, Sung-Ja Ahn, Woong-Ki Chung, Ick Joon Cho, Yong-Hyub Kim, Shin Haeng Cho, Seung Il Jung, Taek Won Kang, Dong Deuk Kwon, Jason Chia-Hsun Hsieh. Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer. PLOS ONE 2021; 16(3): e0248461 doi: 10.1371/journal.pone.0248461
|
| 5 |
Michael R. Odom, Elena S. Pak, Johanna L. Hannan. Ex vivo Akt inhibition reverses castration induced internal pudendal artery and penile endothelial dysfunction. Life Sciences 2021; 285: 119966 doi: 10.1016/j.lfs.2021.119966
|
| 6 |
Jessica Delgado, Jesse Ory, Justin Loloi, Nicholas A Deebel, Ari Bernstein, Sirpi Nackeeran, Isaac Zucker, Ranjith Ramasamy. Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer. Cureus 2022; doi: 10.7759/cureus.32699
|
| 7 |
Amardeep S. Grewal, Caitlin Schonewolf, Eun Jeong Min, Hann-Hsiang Chao, Stefan Both, Sarah Lam, Susan Mazzoni, Justin Bekelman, John Christodouleas, Neha Vapiwala. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 2019; 105(4): 713 doi: 10.1016/j.ijrobp.2019.05.069
|
| 8 |
Yuki Kato, Kazuyoshi Shigehara, Shohei Kawaguchi, Kouji Izumi, Yoshifumi Kadono, Atsushi Mizokami. Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy. The Aging Male 2020; 23(5): 1210 doi: 10.1080/13685538.2020.1731450
|
| 9 |
Kenta Miki, Hiroshi Sasaki, Masahito Kido, Hiroyuki Takahashi, Manabu Aoki, Shin Egawa. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer. BMC Cancer 2016; 16(1) doi: 10.1186/s12885-016-2737-8
|
| 10 |
Ada S Cheung, Alistair J Tinson, Stefan V Milevski, Rudolf Hoermann, Jeffrey D Zajac, Mathis Grossmann. Persisting adverse body composition changes 2 years after cessation of androgen deprivation therapy for localised prostate cancer. European Journal of Endocrinology 2018; 179(1): 21 doi: 10.1530/EJE-18-0117
|
| 11 |
Synne-Kristin Hoffart Bøhn, Sophie Dorothea Fosså, Torbjørn Wisløff, Lene Thorsen. Physical activity and associations with treatment-induced adverse effects among prostate cancer patients. Supportive Care in Cancer 2019; 27(3): 1001 doi: 10.1007/s00520-018-4389-5
|
| 12 |
Suguru Kadomoto, Kazuyoshi Shigehara, Hiroaki Iwamoto, Hiroshi Yaegashi, Kouji Izumi, Yoshifumi Kadono, Atsushi Mizokami. Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review. The World Journal of Men's Health 2020; 38(1): 132 doi: 10.5534/wjmh.180130
|
| 13 |
Almudena Zapatero, Ana Álvarez, Araceli Guerrero, Xavier Maldonado, Carmen González San Segundo, María A. Cabeza, Carmen Martín de Vidales, Josep M. Solé, Agustí Pedro Olivé, Francesc Casas, Ana Boladeras, María L. Vázquez de la Torre, Susana Vara, Felipe.A. Calvo. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. Radiotherapy and Oncology 2021; 160: 115 doi: 10.1016/j.radonc.2021.04.018
|
| 14 |
Hideyasu Tsumura, Nobumichi Tanaka, Tomohiko Oguchi, Takuya Owari, Yasushi Nakai, Isao Asakawa, Kazuyoshi Iijima, Haruaki Kato, Iwao Hashida, Ken-ichi Tabata, Takefumi Satoh, Hiromichi Ishiyama. Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-15028-6
|
| 15 |
Hideyasu Tsumura, Hiromichi Ishiyama, Ken‐ichi Tabata, Hiroki Katsumata, Momoko Kobayashi, Masaomi Ikeda, Shinji Kurosaka, Tetsuo Fujita, Masashi Kitano, Takefumi Satoh, Nobuyuki Yanagisawa, Kazushige Hayakawa, Masatsugu Iwamura. Impact of five‐tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high‐dose‐rate brachytherapy. The Prostate 2017; 77(15): 1520 doi: 10.1002/pros.23430
|
| 16 |
Takahiro Inoue, Takashi Mizowaki, Daijiro Kabata, Ayumi Shintani, Naoki Terada, Toshinari Yamasaki, Hiromitsu Negoro, Takashi Kobayashi, Kiyonao Nakamura, Haruo Inokuchi, Osamu Ogawa. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study. Clinical Genitourinary Cancer 2018; 16(2): 135 doi: 10.1016/j.clgc.2017.09.009
|
| 17 |
Bruno Nascimento, Eduardo P. Miranda, Lawrence C. Jenkins, Nicole Benfante, Elizabeth A. Schofield, John P. Mulhall. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer. The Journal of Sexual Medicine 2019; 16(6): 872 doi: 10.1016/j.jsxm.2019.03.273
|
| 18 |
Kazuhiro Matsumoto, Naoya Niwa, Takeo Kosaka, Toshikazu Takeda, Yota Yasumizu, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Toshiaki Shinojima, Hiroshi Asanuma, Mototsugu Oya. Negative impact of neoadjuvant hormonal therapy on detecting biochemical recurrence after radical prostatectomy. International Journal of Clinical Oncology 2021; 26(9): 1722 doi: 10.1007/s10147-021-01942-8
|
| 19 |
Daniel J George, David P Dearnaley. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer. Future Oncology 2021; 17(33): 4431 doi: 10.2217/fon-2021-0575
|
| 20 |
Masashi Arai, Takeo Kosaka, Yota Yasumizu, Toshikazu Takeda, Kazuhiro Matsumoto, Mototsugu Oya. Androgen deprivation therapy duration is significantly associated with Testosterone recovery in Japanese patients with prostate cancer. International Journal of Urology 2023; 30(2): 235 doi: 10.1111/iju.15098
|
| 21 |
Sarthak Shah, Abigail Pepin, Matthew Forsthoefel, Jessica Burlile, Brian T Collins, Suy Simeng, Nima Aghdam, Sean Collins. Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT). Cureus 2023; doi: 10.7759/cureus.44440
|
| 22 |
Akinori Takei, Shinichi Sakamoto, Ken Wakai, Takaaki Tamura, Yusuke Imamura, Minhui Xu, Maihulan Maimaiti, Koji Kawamura, Takashi Imamoto, Akira Komiya, Koichiro Akakura, Tomohiko Ichikawa. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy. International Journal of Urology 2018; 25(4): 352 doi: 10.1111/iju.13521
|
| 23 |
Fiona Teeling, Nicholas Raison, Majed Shabbir, Tet Yap, Prokar Dasgupta, Kamran Ahmed. Testosterone Therapy for High-risk Prostate Cancer Survivors: A Systematic Review and Meta-analysis. Urology 2019; 126: 16 doi: 10.1016/j.urology.2018.07.064
|
| 24 |
Rihito Aizawa, Kenji Takayama, Kiyonao Nakamura, Takahiro Inoue, Toshinari Yamasaki, Takashi Kobayashi, Shusuke Akamatsu, Osamu Ogawa, Takashi Mizowaki. Increased risk of disease progression in younger men: Analysis of factors predicting biochemical failure and castration-resistant prostate cancer after high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations 2021; 39(2): 131.e9 doi: 10.1016/j.urolonc.2020.09.026
|